Page 43 - Amgen News Today

U.S. Food and Drug Administration fast-tracks approval for Amgen drug shown to shrink lung tumours

Continued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.

The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).

The Dow Jones Industrial Average hit 40,000 points for the first time, though it fell back before closing.

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

/PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its...

Amgen announced that the U.S. Food and Drug Administration has approved IMDELLTRA? for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or...

FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer.

As we previously reported, the Judicial Panel on Multidistrict Litigation recently granted Regeneron Pharmaceutical's ("Regeneron") motion to establish a multi-district litigation ("MDL")...

Foundations Investment Advisors LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,758 shares of the medical research company’s stock after selling 979 shares during the […]